Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement
MWN-AI** Summary
On October 15, 2025, Cosmos Health Inc. (NASDAQ:COSM), a diversified global healthcare group, announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company received official notice from Nasdaq confirming adherence to Listing Rule 5550(a)(2), which mandates a minimum closing bid price of $1.00 per share. Notably, Cosmos Health's stock maintained a bid price at or above this threshold for 18 consecutive business days, beginning September 22, 2025.
Greg Siokas, CEO of Cosmos Health, expressed satisfaction with the company's accomplishment, emphasizing that the compliance was achieved organically. This is indicative of successful execution of its strategic initiatives and improvements in operational fundamentals. He reiterated the company's commitment to providing enduring value for shareholders through innovation, operational excellence, and a robust diversification strategy, including an ongoing digital asset strategy.
Cosmos Health, established in 2009 and incorporated in Nevada, operates through subsidiaries that manufacture and distribute pharmaceuticals, food supplements, cosmetics, and medical devices, including compliance with European Good Manufacturing Practices (GMP). The company's portfolio includes proprietary brands and is involved in R&D partnerships targeting critical health conditions such as obesity, diabetes, and cancer. Additionally, the company has entered the telehealth market with its acquisition of ZipDoctor, Inc.
With a global distribution network, Cosmos Health is expanding its presence in Europe, Asia, and North America. The company maintains offices and distribution centers in Greece and the UK, positioning itself for continued growth in the healthcare sector. Investors are encouraged to understand potential risks outlined in the company's SEC filings, as actual results may differ from projections.
MWN-AI** Analysis
Cosmos Health Inc. (NASDAQ:COSM) has successfully regained compliance with Nasdaq's minimum bid price requirement, a significant milestone that emphasizes the company's stability and potential for growth. The notice from Nasdaq confirmed that the closing bid price of Cosmos Health’s stock has remained above $1.00 for 18 consecutive business days, thereby lifting the compliance issue that had previously posed risks to investor confidence.
This development is critical for investors looking to capitalize on healthcare sector opportunities. With CEO Greg Siokas emphasizing organic growth driven by strategic initiatives, there is a clear indication that Cosmos Health is committed to enhancing its operational fundamentals. This regained compliance not only reinstates the company’s credibility in the eyes of investors but also lays the groundwork for potential institutional investment.
Cosmos Health's diversified portfolio, which includes proprietary pharmaceutical and nutraceutical brands, positions it well within the competitive healthcare landscape. The company's expansion into telehealth through the acquisition of ZipDoctor, alongside its focus on R&D partnerships targeting major health disorders, underscores its forward-thinking approach.
Investors should consider the long-term implications of this compliance notification as a positive indicator of the company's trajectory, especially as it expands across Europe, Asia, and North America. However, it is crucial to remain cognizant of the inherent risks outlined in their forward-looking statements. Factors such as market volatility, financing challenges, and geopolitical tensions (e.g., the war in Ukraine) could impact performance.
In conclusion, Cosmos Health presents a compelling case for investment, particularly as it embarks on a phase of potential growth and innovation. With a renewed compliance status, investors might view this as an opportune time to assess their positions in the stock, balanced against the inherent market uncertainties.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that on October 15, 2025, it received written notice (the ”Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Listing Rule”).
In the Notice, Nasdaq stated that for the last 18 consecutive business days, from September 22, 2025, to October 15, 2025, the closing bid price of the Company’s common stock has been at or above $1.00 per share. Accordingly, the Company is now in compliance with the Listing Rule, and Nasdaq has closed the matter.
Greg Siokas, CEO of Cosmos Health, stated: “We are very pleased to have regained compliance with Nasdaq’s minimum bid price requirement. Importantly, this was achieved organically, reflecting the continued execution of our strategic initiatives and the strengthening of our fundamentals. We remain focused on creating enduring value for our shareholders, guided by our commitment to innovation, operational excellence, and diversification, including the ongoing implementation of our digital asset strategy.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website ( www.sec.gov ). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
Disclaimer
This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a COSM financial position. COSM financial position and all other information regarding the featured Company should be verified directly with COSM. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in COSM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of COSM shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Compensation: Market Wire News and its affiliates has received six thousand dollars for Market Wire News advertising services from Relqo Media LLC for Brand Awareness Distribution, Corporate Communications, News, Press Release Enhancement and Social Media Solutions starting 2026-05-31 and ending 2026-06-05 provided by Market Wire News. To date, we have received a total of six thousand dollars. Please read our full disclaimer for compensation and more detailed information.
FAQ**
What specific strategic initiatives did Cosmos Holdings Inc. (COSM) implement to regain compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price?
How does Cosmos Holdings Inc. (COSM) plan to leverage its digital asset strategy to enhance shareholder value following its compliance with Nasdaq requirements?
Can you provide insights on the R&D partnerships Cosmos Holdings Inc. (COSM) is pursuing, particularly in addressing major health disorders like obesity and diabetes?
What potential risks does Cosmos Holdings Inc. (COSM) foresee that could impact its ability to maintain compliance with Nasdaq listing requirements in the future?
**MWN-AI FAQ is based on asking OpenAI questions about Cosmos Health Inc. (NASDAQ: COSM).
NASDAQ: COSM
COSM Trading
-3.36% G/L:
$0.2505 Last:
367,675 Volume:
$0.264 Open:
